AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

March 5, 2019

NEW YORK--(BUSINESS WIRE)--Mar 5, 2019--Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces participation at the following upcoming industry conferences:

  • Cowen and Company 39th Annual Health Care Conference
    • Kinnari Patel, Pharm.D., MBA, COO, Jonathan Schwartz, M.D., CMO, and Claudine Prowse, Ph.D., SVP, Strategy, and IRO will participate in a fireside chat on Tuesday, March 12, 2019, at 10:40 a.m. Eastern Time.
  • Alliance for Regenerative Medicine Cell & Gene Investor Day
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Thursday, March 21, 2019, at 9:55 a.m. Eastern Time.
  • American College of Cardiology 2019 Annual Meeting
    • Three abstracts from the Danon disease program have been selected for poster sessions at ACC19, which is being held March 16-18, 2019 in New Orleans, LA. Further information is available in the meeting’s official planner available here.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Rocket’s additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for a devastating, pediatric heart failure indication, Danon disease. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190305005242/en/

CONTACT: Claudine Prowse, Ph.D.

SVP, Strategy, Corporate Development and IRO

Rocket Pharma, Inc.

The Empire State Building, Suite 7530

New York, NY 10118

www.rocketpharma.com

investors@rocketpharma.com

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS PHARMACEUTICAL

SOURCE: Rocket Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 03/05/2019 07:00 AM/DISC: 03/05/2019 07:01 AM

http://www.businesswire.com/news/home/20190305005242/en